HitGen, Inc. Hits Day Low at CNY 35.66 Amid Price Pressure

HitGen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 6.56% on August 21, 2026, reaching an intraday low of CNY 35.66. This performance stands in contrast to the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Despite the recent downturn, HitGen has demonstrated strong performance metrics over the longer term. The company has achieved a remarkable 62.15% increase over the past year, significantly outperforming the China Shanghai Composite's 3.56% gain. Additionally, HitGen's year-to-date performance of 54.2% further highlights its resilience in a fluctuating market. Financially, HitGen reported a substantial growth in net profit of 114.98% and a pre-tax profit of CNY 43.75 million, reflecting a growth rate of 150.73%. The company also boasts a robust operating cash flow of CNY 204.8 million and a return on capital employed (ROCE) of 8.01%, indicating effective management of resources. With a market capitalization of CNY 15,382 million, HitGen remains a significant entity within its industry.